SLC25A26 and neoplasm: Convergent analysis yielded 15 high‐confidence candidates associated with tumor rejection, including previously established immunotherapy targets (Alk, Spi1), cytoskeleton regulators (Baiap2, 2610034B18Rik/Arpin), mitochondrial components (Chchd4, Cox5a, Hsd17b10, Slc25a26, Mars2), histone chaperones (Nap1l4, Spty2d1), RNA processing factors (Parn, Tra2a), and uncharacterized genes (1700001O22Rik/C9orf50, Vmn1r191) (Figure 1B, Figure S1H) [30, 31].